Imfinzi Regimen Shows Promise in Early Gastric and GEJ Cancer
The Phase III MATTERHORN trial has yielded significant results for patients with early-stage gastric and gastroesophageal cancers.
Nancy Ghattas, VP, US Oncology Commercial Franchise Head of Immuno-Oncology at AstraZeneca, discussed the trial's findings in a video interview with Applied Clinical Trials.
The Imfinzi-based perioperative regimen demonstrated a 22% reduction in the risk of death and improved overall survival regardless of PD-L1 status.
This marks the first immunotherapy in this setting to show a survival benefit, redefining outcomes for patients with early-stage gastric and gastroesophageal cancers.
Author's summary: Imfinzi regimen reduces risk of death by 22% in gastric and GEJ cancer patients.
More News
- Jimmy Butler issues “scary” warning to the rest of the NBA amid Warriors’ 4-1 start
- The Sixers appeared to finally run out of energy. Then, Adem Bona happened
- Xbox Network and Minecraft Go Down After Major Microsoft Azure Outage | iPhone in Canada
- Western intelligence says Iran is rearming despite UN sanctions, with China’s help | News Channel 3-12
- South Korea is up in arms – and that’s a good thing for European defences - Monocle
- This New Spy Thriller Series Took Over Netflix and Hit #3 Overnight
- Coal power and the Philippine’s energy conglomerates
- The Sopranos Almost Had a Disastrously Obvious Main Theme Song
- Secret history of Hong Kong actor ‘Benz Hung’ Hui Shiu-hung’s merchant family
- France Activates World’s First Highway That Charges Electric Cars and Trucks As They Drive